Candriam S.C.A. Sells 14,804 Shares of Moderna, Inc. (NASDAQ:MRNA)

Candriam S.C.A. cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 2.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 612,862 shares of the company's stock after selling 14,804 shares during the quarter. Candriam S.C.A. owned approximately 0.16% of Moderna worth $25,483,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Wilmington Savings Fund Society FSB increased its holdings in shares of Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after acquiring an additional 587 shares during the last quarter. Compass Planning Associates Inc acquired a new position in Moderna during the 4th quarter worth $37,000. Venturi Wealth Management LLC lifted its holdings in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after buying an additional 664 shares during the period. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after buying an additional 389 shares during the period. Finally, Blue Trust Inc. lifted its holdings in shares of Moderna by 53.1% in the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock valued at $47,000 after buying an additional 388 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

MRNA has been the subject of several research analyst reports. Piper Sandler restated an "overweight" rating and issued a $69.00 price objective (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. Barclays downgraded Moderna from an "overweight" rating to an "equal weight" rating and reduced their price objective for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Leerink Partners reduced their price objective on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research note on Thursday, January 16th. Morgan Stanley cut their price target on Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a research note on Wednesday, January 15th. Finally, HSBC raised Moderna from a "hold" rating to a "buy" rating and set a $58.00 price target for the company in a research note on Monday, November 18th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Moderna currently has an average rating of "Hold" and a consensus target price of $60.63.

Remove Ads

Moderna Stock Performance

Shares of NASDAQ:MRNA traded up $1.31 during trading on Friday, hitting $35.61. 17,290,858 shares of the stock were exchanged, compared to its average volume of 12,693,394. Moderna, Inc. has a 1-year low of $29.25 and a 1-year high of $170.47. The company has a market capitalization of $13.74 billion, a price-to-earnings ratio of -3.84 and a beta of 1.86. The company's fifty day simple moving average is $36.60 and its 200-day simple moving average is $48.77.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.